Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Century Therapeutics's 5-Year RORE % for the quarter that ended in Mar. 2026 was -11.96%.
The industry rank for Century Therapeutics's 5-Year RORE % or its related term are showing as below:
IPSC's 5-Year RORE % is ranked worse than 52.56% of 1132
companies
in the Biotechnology industry
Industry Median: -10.605
vs IPSC: -11.96
Century Therapeutics (NAS:IPSC) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Century Therapeutics 5-Year RORE % Related Terms
Century Therapeutics 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Century Therapeutics's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IPSC vs PBYI, BNTC, ENTA: 5-Year RORE % Comparison
For the Biotechnology subindustry, Century Therapeutics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Century Therapeutics 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Century Therapeutics's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Century Therapeutics (IPSC) has a 5-Year RORE % of -11.96 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Century Therapeutics and its competitors. According to the industry distribution chart, Century Therapeutics ranks #595 out of 1132 companies in the Biotechnology industry, placing it in the top 52.6%.
Is Century Therapeutics' 5-Year RORE % too high?
Century Therapeutics' current 5-Year RORE % is -11.96. Based on the distribution chart, Century Therapeutics ranks #595 out of 1132 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' 5-Year RORE % compare to PBYI and BNTC?
According to the Biotechnology industry distribution chart, Century Therapeutics ranks #595 out of 1132 companies for 5-Year RORE %. This places Century Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current 5-Year RORE % is -11.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current 5-Year RORE % is -11.96. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current 5-Year RORE % is -11.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Century Therapeutics (IPSC) Overvalued in 2026?
Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued.
The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91.
GuruFocus considers Century Therapeutics to be Possible Value Trap.
Key valuation signals for IPSC:
5-Year RORE %: -11.96
GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score
Get the complete analysis for IPSC
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPSC has been successfully added to your 
